피리도스티그민

항콜린에스테라제

브롬화 피리도스티그민은 합성 4급 암모늄 항콜린에스테라제 약물로, 수의학에서는 주로 개(드물게 고양이)의 **중증 근무력증(MG)** 관리에 사용됩니다. * **임상 요점:** 4급 암모늄 구조로 인해 표준 치료 용량에서는 혈액-뇌 장벽을 쉽게 통과하지 못합니다. 따라서 중추신경계(CNS) 부작용을 일으키지 않으면서 MG와 같은 말초 신경근 접합부 질환을 표적으로 삼는 데 이상적입니다. * 일반적으로 선천성 질환보다 **후천성 중증 근무력증**에 훨씬 더 효과적인 것으로 간주됩니다. * 흡수가 불규칙하고 치료 지수가 좁기 때문에 근력 개선과 콜린성 독성 위험 사이의 균형을 맞추어 효과에 따라 용량을 주의 깊게 조절해야 합니다.

작용 기전: **Pyridostigmine** acts as a reversible, competitive inhibitor of the enzyme **acetylcholinesterase (AChE)** at the neuromuscular junction. * **Mechanism:** Pyridostigmine competes directly with **acetylcholine (ACh)** for attachment to AChE. The resulting pyridostigmine-AChE complex is hydrolyzed much more slowly than the natural ACh-AChE complex. * **Pathway:** Inhibition of AChE → Decreased breakdown of ACh → Accumulation of ACh in the synaptic cleft → Prolonged and increased stimulation of **nicotinic ACh receptors** on the motor endplate → Enhanced skeletal muscle contraction and improved strength in myasthenic patients.

동물 종별 용량

Cats

Myasthenia gravis (MG) · 0.5-3 mg/kg daily PO in divided doses · PO · Divided daily · Dose depending on response.
Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h · PO · q8-12h
Myasthenia gravis (MG) · 0.5-3 mg/kg PO per day · PO · Daily · Given with corticosteroids.
Myasthenia gravis · 0.25 mg/kg · PO · q8-12h

Dogs

Myasthenia gravis (MG) · 1-3 mg/kg PO q8-12h. For animals that cannot tolerate oral medications, it may be used as an IV constant rate infusion at 0.01-0.03 mg/kg/hour. · PO/IV · q8-12h or CRI · Titrate to effect to minimize adverse effects and maximize muscle strength.
Myasthenia gravis (MG) · 0.5-3 mg/kg PO q8-12 hours with food. · PO · q8-12h · Start low and increase slowly. Liquid formulation recommended for easy adjustment. An H2 antagonist (e.g., famotidine 5 mg/kg/day) may reduce nausea/GI irritation.
Acquired Myasthenia gravis (MG) · 7.5-30 mg PO two times a day. · PO · BID · Begin after oral regurgitation is abolished with parenteral neostigmine. Once stable, begin corticosteroids for 2 weeks, then gradually reduce pyridostigmine.
Myasthenia gravis (MG) · 0.5-3 mg/kg PO two to three times a day. · PO · BID-TID · If no response, add prednisone.
Myasthenia gravis (MG) · 0.5-1 mg/kg PO two to three times a day · PO · BID-TID · With or without prednisone (2 mg/kg PO twice daily). Spontaneous remission is not uncommon.

투여 경로

POIVIM

금기

Hypersensitivity to anticholinesterase compounds or bromides
Mechanical or physical obstructions of the urinary tract
Mechanical or physical obstructions of the gastrointestinal (GI) tract
Mechanical gastrointestinal obstruction
Mechanical urinary tract obstruction
Peritonitis

이상반응

Nausea
Vomiting
Diarrhea
Excessive salivation (ptyalism)
Sweating (in species with sweat glands)
Increased bronchial secretions
Bronchospasm
Pulmonary edema
Respiratory paralysis
Miosis (pupil constriction)
Blurred vision
Lacrimation (tearing)
Bradycardia
Tachycardia
Cardiospasm
Hypotension
Cardiac arrest

약물 상호작용

Atropine · Antagonizes the muscarinic effects of pyridostigmine. Use cautiously as it can mask early clinical signs of a life-threatening cholinergic crisis.
Corticosteroids · May decrease the anticholinesterase activity of pyridostigmine. Discontinuing corticosteroids may suddenly increase anticholinesterase activity, requiring dose adjustments.
Dexpanthenol · Theoretically may have additive cholinergic effects when used concurrently.
Neuromuscular blocking drugs (e.g., aminoglycosides) · May necessitate increased dosages of pyridostigmine when treating or diagnosing myasthenic patients.
Magnesium (parenteral) · Can antagonize anticholinesterase therapy due to its direct depressant effect on skeletal muscle.
Muscle Relaxants · May prolong the Phase I block of depolarizing muscle relaxants (e.g., succinylcholine) and antagonize the actions of non-depolarizing agents (e.g., pancuronium, atracurium).
Aminoglycosides · May antagonize the neuromuscular effects of pyridostigmine · moderate
Clindamycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
Lincomycin · May antagonize the neuromuscular effects of pyridostigmine · moderate
Propranolol · May antagonize the effects of pyridostigmine · moderate
Suxamethonium · Pyridostigmine may enhance the effect of depolarizing muscle relaxants · major

모니터링

Clinical signs of cholinergic toxicity (salivation, lacrimation, urination, defecation, GI upset, emesis, weakness)
Efficacy of therapy (improvement in muscle strength, reduction of megaesophagus/regurgitation)
Respiratory rate and effort
Improvement in muscle strength and exercise tolerance
Signs of muscarinic toxicity (hypersalivation, vomiting, diarrhea, miosis)
Heart rate and rhythm
Respiratory rate and effort (especially in patients with megaoesophagus)

과용량

Overdosage of pyridostigmine can induce a life-threatening **cholinergic crisis**. * **Clinical Signs (SLUDGE syndrome):** GI effects (nausea, vomiting, diarrhea), excessive salivation, sweating, respiratory distress (increased bronchial secretions, bronchospasm, pulmonary edema, respiratory paralysis), ophthalmic effects (miosis, blurred vision, lacrimation), cardiovascular collapse (bradycardia, tachycardia, hypotension, cardiac arrest), severe muscle cramps, and profound weakness. * **Diagnostic Challenge:** Overdoses in myasthenic patients can be very difficult to distinguish from a **myasthenic crisis** (disease exacerbation). The time of onset of clinical signs or an **edrophonium challenge** (Tensilon test) may help differentiate the two. * **Treatment:** Consists of immediate respiratory and cardiac supportive therapy. **Atropine** should be administered to antagonize muscarinic effects (refer to atropine protocols for cholinergic toxicity).

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.